Business
CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update
Strong positive sales trajectory for rhCollagen based productsContinued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"Strong positive sales trajectory for rhCollagen based productsContinued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human Collagen Readying sites to begin large-animal study planned in the second half of 2023 to advance 3D bioprinted regenerative breast implant programConference call to be held on May 24, 2023 at 10:00 am U.S. ET; Dial-in information hereinREHOVOT, Israel, May 24, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update on its programs.\n\n \n \n \n \n \n \n\n \n\"Recently, we announced a collaborative agreement with Stratasys, a world-leader in 3D printing as well as completed the first large-animal study for our 3D bioprinted regenerative breast implants,\" said CollPlant's Chief Executive Officer, Yehiel Tal. \"The agreement with Stratasys allows us to utilize their proprietary 3D printer technology and combine this with our state-of-the-art rhCollagen-based bioinks to enable high-resolution, scalable, and reproduceable bioprinting of scaffolds that accurately mimic the physical properties of human tissues and organs. The combined proprietary technologies will allow for 3D tissue and organ fabrication that also possess differentiated, regenerative properties.\"\nMr. Tal continued, \"In addition, in the first quarter of 2023, we successfully completed a large-animal study for our regenerative breast implants as a precursor to a second large-animal study that we plan to initiate in the second half of this year. Trial sites are currently being secured and we look forward to providing an update as soon as this study begins. Our production of regenerative, non-animal derived, recombinant human collagen is the hallmark of our technology platform and continues to show promise for broad application spectrum.\"\nRecent Corporate Highlights\nProgram development \nIn January 2023, CollPlant announced that it successfully completed a large-animal study for its 3D bioprinted regenerative breast implants. The preclinical study demonstrated pr...